{
    "attributes": {
        "action": "Parliament to modify a rule* that stops the NHS from saving money on a drug.",
        "additional_details": "NHS patients with age-related macular degeneration took part in the IVAN study in 2008.\r\n\r\nThe MHRA's Guidance Note 14 specifically prohibits* obtaining a licensed special medicine in order to save money. \r\n\r\nThe appropriateness of this sanction when applied to the unique circumstance of Lucentis & Avastin merits parliamentary debate to change this law.\r\n\r\nhttps://www.gov.uk/government/uploads/system/uploads/attachment_data/file/373505/The_supply_of_unlicensed_medicinal_products__specials_.pdf",
        "background": "This is a unique situation.  One Swiss pharmaceutical company makes 2 very similar medicines: ranibizumab, known by its trade name Lucentis, and bevacizumab ( Avastin).  However Lucentis is 80 times more expensive than Avastin.\r\nResearch has shown that both drugs can prevent blindness equally. ",
        "closed_at": "2016-12-30T23:59:59.999Z",
        "created_at": "2016-06-10T08:02:12.248Z",
        "creator_name": null,
        "debate": null,
        "debate_outcome_at": null,
        "debate_threshold_reached_at": null,
        "government_response": null,
        "government_response_at": null,
        "moderation_threshold_reached_at": "2016-06-11T13:56:42.765Z",
        "open_at": "2016-06-30T10:12:47.994Z",
        "rejected_at": null,
        "rejection": null,
        "response_threshold_reached_at": null,
        "scheduled_debate_date": null,
        "signature_count": 635,
        "state": "closed",
        "updated_at": "2017-03-31T14:20:20.536Z"
    },
    "id": 132381,
    "links": {
        "self": "https://petition.parliament.uk/petitions/132381.json"
    },
    "type": "petition"
}